Related references
Note: Only part of the references are listed.DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma
John M. Burke et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Targeting the B cell receptor pathway in non-Hodgkin lymphoma
Kelly Valla et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Improved Adherence Rates and Clinical Outcomes of an Integrated, Closed-Loop, Pharmacist-Led Oral Chemotherapy Management Program
Benyam Muluneh et al.
JOURNAL OF ONCOLOGY PRACTICE (2018)
Adherence to oral anticancer medications after implementation of an ambulatory adherence program at a large urban academic hospital.
Marjorie Adams Curry et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
F. Morschhauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries
Jan Geissler et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States
Qiushi Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment
Amanda Pereira-Salgado et al.
JMIR MHEALTH AND UHEALTH (2017)
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Paul M. Barr et al.
BLOOD (2017)
A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
Andrew M. Evens et al.
CLINICAL CANCER RESEARCH (2016)
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
Lauren R. Teras et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma
Michael Crump et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature
Daniel Eek et al.
PATIENT PREFERENCE AND ADHERENCE (2016)
Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia
Masha S. H. Lam et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2016)
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma
T. E. Witzig et al.
ANNALS OF ONCOLOGY (2015)
An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia
Jeff Sharman et al.
BLOOD (2015)
Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients
Susanne Liewer et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
John G. Gribben et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Shundong Cang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase
Annie Guerin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
Stacie B. Dusetzina et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
M. Wang et al.
LEUKEMIA (2013)
The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience
S. Yousuf Zafar et al.
ONCOLOGIST (2013)
A Proposal for Quality Standards for Measuring Medication Adherence in Research
Ann Bartley Williams et al.
AIDS AND BEHAVIOR (2013)
Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia
Adam Gater et al.
LEUKEMIA RESEARCH (2012)
Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients
Eric Q. Wu et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral Cancer Chemotherapy: The Critical Interplay Between Patient Education and Patient Safety
Thorvardur R. Halfdanarson et al.
CURRENT ONCOLOGY REPORTS (2010)
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
Lucien Noens et al.
BLOOD (2009)
Treatment interruptions and non-adherence with imatinib and associated healthcare costs - A retrospective analysis among managed care patients with chronic myelogenous leukaemia
Theodore Darkow et al.
PHARMACOECONOMICS (2007)
Share Paper
